Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?

Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) are almost opposites in the pharmaceutical market. One is trying to replace revenue from aging blockbusters, while the other is struggling to keep pace with demand for its newest ones. Yahoo Finance’s most recently available valuation statistics show that Bristol Myers trades at 9.36 times […]